- Tytuł:
- Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
- Autorzy:
- Źródło:
- In The Lancet Oncology May 2023 24(5):496-508
Czasopismo naukowe